FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel compounds, which possess qualities to estrogen modulators, of general formula (1) 
or its pharmaceutically acceptable salt, where R1 represents hydrogen atom or (C1-C6)alkyl, -SO2NR7R8, phenyl (C1-C3)alkyl or (C1-C3)alkyl, substituted with 5-8-member heterocyclic radical, containing nitrogen atom; R2 and R3 each independently represents hydrogen atom or hydroxyl, halogen atom or (C1-C6)alkoxy; X represents O, S, SO, SO2 or NR4; R4 represents hydrogen atom or (C1-C6)alkyl, phenyl, phenyl(C1-C3)alkyl, (C1-C3)alkyl, substituted with 5-8-member saturated heterocyclic radical, containing one nitrogen atom, or group -COR7, -CO2R7 or -SO2NR7R8, where phenyl is not substituted or is substituted with at least one substituent, selected from group which includes hydroxyl, halogen atom or phenyl(C1-C3)alkoxy; Y represents direct bond, -(CR10R11)n- or -R10C=CR11-; R7 and R8 each independently represents hydrogen atom or (C1-C6)alkyl group; R10 and R11 each independently represent hydrogen atom or cyano, or group CONR7R8; n equals 1 or 2; A represents (C3-C12)cycloalkyl or phenyl, where phenyl is not substituted or is substituted with at least one substituent, selected from group which includes hydroxyl, halogen atom, (C1-C3)alkyl, (C1-C3)alkoxy; when X represents NR4, Y and R2 together with containing them indazole cycle can also form 1H-pyrano[4,3,2-cd)indazole; on condition that: 1) when X represents O, S or NR4, R1 represents hydrogen atom or (C1-C6)alkyl, and Y stands for direct bond, then A is not optionally substituted phenyl; 2) when X represents O, R1O represents 6-OH or 6-OCH3, Y represents direct bond and A represents cyclopeptyl, then (R2, R3) or (R3, R2) are different from (H, CI) in position 4, 5; 3) when X stands for O, R1O represents 6-OH, R2 and R3 represent H, and Y represents CH=CH, then A is not phenyl or methoxyphenyl; 4) when X represents SO2, A represents phenyl and R1O represents 5-or 6-OCH3, then (R2, R3) or (R3, R2) are different from (H, OCH3) in position 6- or 5-, compound not being one of the following: 3-phenyl-5-(phenylmethoxy)-1H-indazole; n-hydroxy-3-phenylmethyl-7-(n-propyl)-benz[4,5]isoxazole; 3-(4-chlorphenylmethyl)-6-hydroxy-7-(n-propyl)-benz[4,5]isoxazole; 6-hydroxy-3-(2-phenylethyl)-7(n-propyl)-benz[4,5]isoxazole; 3-cyclopropyl-6-hydroxy-3-phenylmethyl-7-(n-propyl)-benz[4,5|isoxazole; 3-cyclohexylmethyl-6-hydroxy-3-phenylmethyl-7-propyl-benz[4,5]isoxazole. Invention also relates to pharmaceutical composition, application and method of prevention and treatment of disease, where modulation of estrogen receptors is required.
EFFECT: obtaining novel compounds, which possess qualities of estrogen receptors modulators.
18 cl, 7 dwg, 8 tbl, 97 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMIDAZOLE DERIVATIVES AS TAFIa INHIBITORS | 2005 |
|
RU2375356C2 |
| ACRIDINE DERIVATIVES, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2001 |
|
RU2267488C2 |
| DERIVATIVES OF PYRAZOLE AS MEDICINAL AGENTS FOR TREATMENT OF DISEASES THAT OCCUR AS RESULT OF DISFUNCTION OF NICOTINE RECEPTORS ALFA7 | 2004 |
|
RU2376290C2 |
| 5-SUBSTITUTED INDAZOLE AS KINASE INHIBITORS | 2008 |
|
RU2487873C2 |
| NEW SUBSTITUTED 8-HETEROARYLXANTINES AND BASED PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2357969C2 |
| IMIDAZO[1,2-α]PYRIDINE-2-CABROXAMIDES, MAKING THEM AND APPLYING IN THERAPY | 2007 |
|
RU2441003C2 |
| CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND USE THEREOF IN TREATING PSYCHOTIC DISORDERS | 2011 |
|
RU2586974C2 |
| INDOLE DERIVATIVES, METHOD FOR THEIR PREPARING, MEDICINAL AGENT AND METHOD FOR INHIBITION OF TUMOR CELLS PROLIFERATION | 2001 |
|
RU2270196C9 |
| 1-N-PHENYLAMINO-1H-IMIDAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2004 |
|
RU2365586C2 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
